Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gloria White

Registered Nurse, Psychiatric/Mental Health Greenfield, MA Clinical Nurse Specialist

NPI 1154440964 CMS profile 10704076

13 Prospect St, Greenfield, MA 01301

Open in the dashboard

General payments

$2,436

102 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gloria White of Greenfield, MA is reported in the CMS Open Payments database as having received $2,436 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Registered Nurse, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $932 38
2024 General $479 20
2023 General $799 35
2022 General $115 6
2021 General $112 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gloria White
  • Registered Nurse, Psychiatric/Mental Health median
  • Middle half of Registered Nurse, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Gloria White were reported at $932. Among 280 Registered Nurse, Psychiatric/Mental Health profiles paid that year, the median was $140 and the middle half received between $43 and $515.

Show as a table
Year Gloria White Registered Nurse, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $112 $101 $31–$244 $132
2022 $115 $103 $36–$248 $149
2023 $799 $138 $45–$382 $160
2024 $479 $167 $39–$462 $164
2025 $932 $140 $43–$515 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $452 23 payments
  2. Otsuka America Pharmaceutical, Inc. $340 15 payments
  3. Janssen Pharmaceuticals, Inc $325 9 payments
  4. E.R. Squibb & Sons, L.L.C. $318 5 payments
  5. Vanda Pharmaceuticals Inc. $207 15 payments
  6. Alkermes, Inc. $188 9 payments
  7. Lundbeck LLC $180 7 payments
  8. Indivior Inc. $135 5 payments
  9. ITI, Inc. $119 5 payments
  10. Neurocrine Biosciences, Inc. $88 4 payments
  11. Other $83 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,236 89 payments
  2. Education $200 13 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $411 21 payments
  2. COBENFY $318 5 payments
  3. REXULTI Psychiatry $241 9 payments
  4. FANAPT $207 15 payments
  5. SPRAVATO $194 4 payments
  6. REXULTI Psychiatry $180 7 payments
  7. LYBALVI $167 8 payments
  8. ARISTADA Cns $167 8 payments
  9. ARISTADA Cns $167 8 payments
  10. ARISTADA Cns $146 7 payments
  11. Other $1,014 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

4,538

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$394,863

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

18.7%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 78 $147,465
Lurasidone Hcl Generic 119 $49,535
Rexulti Brexpiprazole Brand 16 $34,179
Caplyta Lumateperone Tosylate Brand 19 $31,102
Trintellix Vortioxetine Hydrobromide Brand 22 $16,451
Belsomra Suvorexant Brand 22 $10,356
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 280 $7,405
Aripiprazole Generic 111 $6,535
Concerta Methylphenidate Hcl Brand 13 $5,400
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 74 $4,702

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$23,105

Medicare's payments for the services billed

Medicare patients

83

Average age 54

Services billed

298

56 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 60%
High blood pressure 35%
Arthritis 30%
Diabetes 19%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $86
  • Otsuka America Pharmaceutical, Inc. $54
$140 16 —
VRAYLAR
  • AbbVie, Inc. $77
$77 78 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $63
$63 — —
CAPLYTA
  • ITI, Inc. $50
$50 19 —
INGREZZA
  • Neurocrine Biosciences, Inc. $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record